Insmed Incorporated — Q1 2024 Form 10-Q
Reporting period: Three months ended March 31, 2024; filed May 9, 2024. Insmed is a global biopharmaceutical company whose only approved product is ARIKAYCE, marketed in the U.S., Europe and Japan. Its principal pipeline programs are brensocatib and treprostinil palmitil inhalation powder (TPIP).
Financial results and position
| Metric | Q1 2024 | Q1 2023 / comparison |
|---|---|---|
| Product revenue, net | $75.5 million | $65.2 million; up 15.8% |
| Operating loss | $145.5 million | $148.2 million |
| Net loss | $157.1 million | $159.8 million |
| Net loss per share, basic and diluted | $1.06 | $1.17 |
| Net cash used in operating activities | $184.0 million | $146.3 million |
| Cash and cash equivalents at period-end | $595.7 million | $482.4 million at Dec. 31, 2023 |
- All product revenue is from ARIKAYCE. U.S. sales were $56.3 million, Japan $14.9 million, and Europe and rest of world $4.3 million.
- Cost of product revenue was $17.5 million, or 23.1% of revenue, versus 21.2% a year earlier; the implied product gross margin was approximately 76.9%, versus 78.8%.
- Research and development expense was $121.1 million, down 5.3%, partly because Q1 2023 included a $10.3 million noncash Vertuis acquisition charge. Selling, general and administrative expense rose 16.5% to $93.1 million, mainly on higher compensation, stock-based compensation and brensocatib commercial-readiness costs.
- Investment income was $8.8 million; interest expense was $21.0 million. The reported loss also reflected a $11.9 million gain from changes in deferred and contingent consideration fair value and a $2.4 million gain on the interest-rate swap.
- Working capital was $337.9 million, down from $703.4 million at year-end, principally reflecting the $300.0 million maturity of marketable securities and the reclassification of $224.2 million of 2025 convertible notes as current. The securities maturity shifted funds into cash; it was not operating cash generation.
- Debt carrying value was approximately $1.16 billion, including $224.2 million of current convertible notes, $565.5 million of long-term 2028 convertible notes and a $373.5 million term loan. The royalty financing liability was separately reported at $157.0 million. Shareholders’ deficit was $464.8 million.
Changes, outlook and significant matters
- Revenue growth was broad-based across the U.S., Japan and Europe/rest of world. Operating loss narrowed modestly, while operating cash use increased by $37.7 million year over year.
- Management expects continued operating losses and substantial cash requirements as it funds ARIKAYCE commercialization, brensocatib and TPIP development, and other research. It stated that available funds should meet needs for at least the next 12 months, while noting it may seek additional capital. A new at-the-market equity program permits up to $500 million in gross sales; no shares had been sold under it by March 31, 2024.
- Brensocatib’s Phase 3 ASPEN trial had completed enrollment; topline results were anticipated in the latter half of Q2 2024. If approved, Insmed anticipated a U.S. launch in mid-2025, followed by Europe and Japan in the first half of 2026. AstraZeneca exercised its second and final option to pursue brensocatib in COPD or asthma, subject to agreement on satisfactory terms; Insmed retains rights in other indications and geographies.
- For ARIKAYCE’s U.S. confirmatory program, ENCORE enrollment continued after reaching the original 250-patient target. Insmed planned to meet with the FDA in late June 2024 to discuss the PRO data and finalize the statistical plan and enrollment target; topline results were expected in 2025. Failure to satisfy the post-marketing requirement could affect full approval.
- After quarter-end, in May 2024, Insmed reported topline safety data and exploratory efficacy endpoints from the Phase 2 TPIP PH-ILD study and planned regulatory discussions toward a Phase 3 study, anticipated to begin in 2025. TPIP PAH Phase 2 topline results were anticipated in 2025.
- Key risks include clinical-trial and regulatory uncertainty, ARIKAYCE’s accelerated-approval status and reimbursement, reliance on a limited number of manufacturers and other third parties, and future financing needs. Three customers represented 35%, 34% and 16% of gross product revenue, respectively. The term loan bears floating-rate interest, partly economically hedged by a swap; royalty financing requires payments tied to ARIKAYCE sales and, if approved, brensocatib sales.
- Management said ordinary-course legal proceedings were not expected to have a material adverse effect. It reported effective disclosure controls and no material change in internal control over financial reporting during the quarter.
Investor verification priorities
- Check ASPEN topline results and any resulting regulatory, safety or launch-timing updates for brensocatib.
- Track FDA feedback and ENCORE’s final design, enrollment target, timing and ability to support ARIKAYCE’s full approval.
- Review TPIP’s complete Phase 2 data and whether the planned PH-ILD Phase 3 design and 2025 start remain achievable.
- Monitor operating cash burn, available liquidity, use of the $500 million ATM program and the approaching January 2025 maturity of the 2025 convertible notes.
- Assess ARIKAYCE sales concentration, customer retention, reimbursement and supply continuity, including reliance on contract manufacturers.
- Follow the term-loan covenants, floating-rate exposure and cumulative royalty-financing payments and obligations.